

## CONTACTS

Robert White  
President and Chief Executive Officer  
TYRX, Inc.  
732.246.8676  
[info@TYRX.com](mailto:info@TYRX.com)

## TYRX Announces the Appointment of Ron Salsbury as Vice President of Quality

**Monmouth Junction, NJ (December 27, 2011)** – TYRX<sup>®</sup>, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections, today announced the appointment of Ron Salsbury as Vice President of Quality.

Mr. Salsbury has over 25 years of experience in the pharmaceutical and medical device industry. His broad experience includes positions in product development, engineering, regulatory, and quality for dental implants (Orthomatrix), orthopedic implants (Osteonics, a division of Stryker), collagen-based soft tissue and nerve repair (Integra LifeSciences), and served most recently as Vice President of Quality Assurance and Regulatory Affairs for Nexgen Spine before joining TYRX. He holds a BS from SUNY at Albany and an MS in Chemistry from Rensselaer Polytechnic Institute. He also has two patents for medical ceramics and manufacturing processes related to medical devices.

“Ron’s extensive experience adds additional strength to our exceptional management team,” said Robert S. White, President and CEO. “Additionally, Ron’s appointment to lead our quality efforts demonstrates our ongoing commitment to provide our customers with reliable and high quality products that consistently meet or exceed their expectations.”

### **About TYRX, Inc.**

TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISR<sup>®</sup>x Antibacterial Envelope & Flat Sheet technologies, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISR<sup>®</sup>x products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in implantable pacemaker and defibrillator related endocarditis, including “superbugs” or MRSA\*. Following commercial release, the AIGISR<sup>®</sup>x Envelope has been implanted in well over 20,000 patients nationwide. The company estimates that over 2% of all U.S. implantable pacemaker and defibrillator patients in 2012 will receive an AIGISR<sup>®</sup>x product during their procedure. TYRX is preparing to commercialize its second AIGISR<sup>®</sup>x technology, the AIGISR<sup>®</sup>x ST, designed to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue. Current research & development projects are focusing on a fully-resorbable version of AIGISR<sup>®</sup>x.

TYRX, Inc. is an ISO 13485:2003 certified medical device manufacturer and its products utilize technology licensed exclusively from Rutgers, Baylor College of Medicine, and The University of Texas M. D. Anderson Cancer Center. For more information, please visit <http://www.tyrx.com>.

\* Based upon preclinical *in vitro* and *in vivo* data. Data on file at TYRX and published in *PACE* 2009; 32(7) 898-907.

###

MKT-23-134 Rev 1